Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 29.32 Million SEK | 925.42% |
| 2022 | 2.86 Million SEK | 20.47% |
| 2021 | 2.37 Million SEK | 0.3% |
| 2020 | 2.36 Million SEK | 38.42% |
| 2019 | 1.71 Million SEK | 436.32% |
| 2018 | 318.84 Thousand SEK | 203.66% |
| 2017 | 105 Thousand SEK | -62.5% |
| 2016 | 280 Thousand SEK | -57.49% |
| 2015 | 658.69 Thousand SEK | -55.52% |
| 2014 | 1.48 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 5.65 Million SEK | -27.04% |
| 2024 Q1 | 7.75 Million SEK | 13.76% |
| 2023 Q3 | 6.68 Million SEK | -12.7% |
| 2023 Q4 | 6.81 Million SEK | 1.99% |
| 2023 FY | 29.32 Million SEK | 925.42% |
| 2023 Q1 | 8.17 Million SEK | 896.71% |
| 2023 Q2 | 7.65 Million SEK | -6.34% |
| 2022 Q2 | 211 Thousand SEK | -29.19% |
| 2022 FY | 2.86 Million SEK | 20.47% |
| 2022 Q4 | 820 Thousand SEK | -46.44% |
| 2022 Q3 | 1.53 Million SEK | 625.59% |
| 2022 Q1 | 298 Thousand SEK | -55.52% |
| 2021 Q2 | 342 Thousand SEK | -36.19% |
| 2021 Q1 | 536 Thousand SEK | -2.19% |
| 2021 FY | 2.37 Million SEK | 0.3% |
| 2021 Q4 | 670 Thousand SEK | -18.89% |
| 2021 Q3 | 826 Thousand SEK | 141.52% |
| 2020 FY | 2.36 Million SEK | 38.42% |
| 2020 Q1 | 1.19 Million SEK | 66.71% |
| 2020 Q3 | 530 Thousand SEK | 446.39% |
| 2020 Q4 | 548 Thousand SEK | 3.4% |
| 2020 Q2 | 97 Thousand SEK | -91.86% |
| 2019 Q2 | 772 Thousand SEK | 664.36% |
| 2019 Q1 | 101 Thousand SEK | -8.05% |
| 2019 FY | 1.71 Million SEK | 436.32% |
| 2019 Q3 | 122 Thousand SEK | -84.2% |
| 2019 Q4 | 715 Thousand SEK | 486.07% |
| 2018 Q3 | 104 Thousand SEK | -88.47% |
| 2018 Q1 | 105 Thousand SEK | -89.52% |
| 2018 Q2 | 902 Thousand SEK | 759.05% |
| 2018 Q4 | 109.84 Thousand SEK | 5.62% |
| 2018 FY | 318.84 Thousand SEK | 203.66% |
| 2017 Q2 | 692 Thousand SEK | 1877.14% |
| 2017 FY | 105 Thousand SEK | -62.5% |
| 2017 Q4 | 1 Million SEK | 1331.16% |
| 2017 Q3 | 70 Thousand SEK | -89.88% |
| 2017 Q1 | 35 Thousand SEK | -93.46% |
| 2016 Q1 | 401 Thousand SEK | 28.24% |
| 2016 Q2 | 175 Thousand SEK | -56.36% |
| 2016 FY | 280 Thousand SEK | -57.49% |
| 2016 Q4 | 534.84 Thousand SEK | 409.38% |
| 2016 Q3 | 105 Thousand SEK | -40.0% |
| 2015 Q3 | 334 Thousand SEK | 78.61% |
| 2015 Q1 | 159 Thousand SEK | 0.0% |
| 2015 Q2 | 187 Thousand SEK | 17.61% |
| 2015 Q4 | 312.69 Thousand SEK | -6.38% |
| 2015 FY | 658.69 Thousand SEK | -55.52% |
| 2014 Q3 | - SEK | -100.0% |
| 2014 FY | 1.48 Million SEK | 0.0% |
| 2014 Q2 | 417 Thousand SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q1 | 417 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | 97.738% |
| Enzymatica AB (publ) | 50.9 Million SEK | 42.388% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -2059.573% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | 20.37% |
| ODI Pharma AB | 22.44 Million SEK | -30.649% |
| Orexo AB (publ) | 638.8 Million SEK | 95.409% |
| Probi AB (publ) | 627.68 Million SEK | 95.328% |
| Swedencare AB (publ) | 2.32 Billion SEK | 98.738% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 99.867% |
| Toleranzia AB | 50.92 Million SEK | 42.406% |
| Vivesto AB | 1.01 Million SEK | -2789.36% |